Larazotide Acetate: Tight Junction Peptide
Celiac Disease Peptides
342 Patients
In a Phase 2 trial of 342 adults with celiac disease on a gluten-free diet, larazotide acetate 0.5 mg reduced symptoms compared to placebo, producing a 26% decrease in symptomatic days.
Leffler et al., Gastroenterology, 2015
Leffler et al., Gastroenterology, 2015
View as imageCeliac disease has no approved drug treatment. The only management option is a lifelong gluten-free diet, and even strict adherence leaves many patients with persistent symptoms. Larazotide acetate (originally designated AT-1001) is a synthetic eight-amino-acid peptide designed to address one specific part of the celiac disease cascade: the opening of tight junctions between intestinal epithelial cells that allows gluten peptides and other molecules to cross the gut barrier and trigger immune reactions.[1]
Slifer et al. (2021) described larazotide as "a pharmacological peptide approach to tight junction regulation," documenting its mechanism of action, clinical trial history, and potential applications beyond celiac disease (Slifer et al., American Journal of Physiology: Gastrointestinal and Liver Physiology, 2021). The peptide reached Phase 3 clinical trials before the CedLara trial was discontinued in June 2022 after an interim analysis showed insufficient separation from placebo. This article covers the full evidence landscape for larazotide acetate: how it works, what the clinical data showed, why Phase 3 failed, and what the results mean for peptide-based approaches to gut barrier diseases. For related coverage, see our articles on gluten-derived peptides and peptide-based celiac treatments.
Key Takeaways
- Larazotide acetate is an eight-amino-acid peptide that blocks zonulin-mediated tight junction opening in the intestinal epithelium (Slifer et al., American Journal of Physiology, 2021)
- In a Phase 2 trial of 342 adults, the 0.5 mg dose reduced celiac symptoms with a 26% decrease in symptomatic days and 31% increase in improved symptom days vs. placebo (Leffler et al., Gastroenterology, 2015)
- The Phase 3 CedLara trial (525 patients) was discontinued in June 2022 after an interim analysis showed the treatment effect was too small to reach statistical significance with feasible enrollment
- Higher doses (1 mg and 2 mg) showed no benefit over placebo in Phase 2, suggesting an inverted dose-response relationship (Leffler et al., Gastroenterology, 2015)
- Zonulin, the endogenous protein that larazotide antagonizes, is elevated in celiac disease and other autoimmune conditions including type 1 diabetes and inflammatory bowel disease
- BPC-157, another peptide studied for gut barrier function, stabilized intestinal permeability through different mechanisms in NSAID-injury models (Park et al., Current Pharmaceutical Design, 2020)
How Tight Junctions Work and Why They Matter in Celiac Disease
Tight junctions are protein complexes that seal the gaps between adjacent intestinal epithelial cells. They form a selective barrier that allows water and small nutrients to pass while blocking larger molecules, bacteria, and undigested protein fragments from crossing into the underlying tissue where immune cells reside.
In celiac disease, this barrier breaks down. When genetically susceptible individuals (carrying HLA-DQ2 or HLA-DQ8 genes, approximately 30-40% of the population) consume gluten, the gliadin fraction of gluten triggers a cascade that opens tight junctions. The key mediator is zonulin, an endogenous protein that binds to receptors on epithelial cells and activates signaling pathways leading to tight junction disassembly. Celiac patients have elevated zonulin expression in intestinal tissue compared to healthy controls.
Once tight junctions open, gliadin peptides (partially digested fragments of gluten proteins, typically 33 amino acids long) cross the epithelial barrier through the paracellular pathway. In the lamina propria, tissue transglutaminase modifies these peptides, creating deamidated gliadin fragments that bind with high affinity to HLA-DQ2/DQ8 molecules on antigen-presenting cells. This triggers a T-cell-mediated immune response that damages the intestinal villi, producing the villous atrophy and malabsorption characteristic of celiac disease.
The tight junction step is upstream of the immune response. If gliadin peptides cannot cross the epithelial barrier, they cannot reach the immune cells that drive tissue damage. This is the therapeutic rationale for larazotide: block tight junction opening before the inflammatory cascade begins.
The tight junction complex itself is a sophisticated structure composed of transmembrane proteins (claudins, occludin, junctional adhesion molecules) and intracellular scaffold proteins (ZO-1, ZO-2, ZO-3) that anchor the complex to the actin cytoskeleton. Over 25 claudin family members have been identified, each conferring different permeability properties. In celiac disease, claudin-2 (a pore-forming claudin that increases permeability) is upregulated while claudin-3 and claudin-4 (barrier-tightening claudins) are redistributed away from the junction. Restoring the normal claudin profile is part of what larazotide appears to do at the molecular level.
How Larazotide Acetate Works
Larazotide acetate is derived from a fragment of Vibrio cholerae's zonula occludens toxin (Zot), which itself mimics human zonulin. The peptide acts as a zonulin receptor antagonist, blocking the signaling cascade that leads to tight junction disassembly.[1]
The mechanism involves several components. Larazotide binds to zonulin receptors on intestinal epithelial cells, preventing zonulin from activating the downstream signaling pathway. This pathway normally involves phosphorylation of myosin light chain kinase (MLCK), which generates tension on actin filaments connected to tight junction proteins. When MLCK is activated, the resulting cytoskeletal contraction physically pulls tight junction proteins apart, creating gaps between cells. By blocking this cascade at the receptor level, larazotide keeps tight junctions assembled.
More recent research has linked larazotide to redistribution and rearrangement of tight junction proteins (occludin, claudins, ZO-1) and actin filaments, suggesting the peptide may actively promote tight junction reassembly in addition to preventing disassembly (Slifer et al., 2021).
Larazotide is administered orally and acts locally in the gut lumen. It is not absorbed systemically in significant quantities, which limits systemic side effects but also means it can only affect tight junctions in the gastrointestinal tract. The peptide is taken three times daily before meals, timed to be present in the intestinal lumen when gluten exposure occurs.
Song et al. (2024) studied FCIGRL, a six-amino-acid fragment derived from the same zonula occludens toxin that inspired larazotide. FCIGRL-modified peptides modulated tight junctions to enhance intestinal absorption of the chemotherapy drug doxorubicin, demonstrating that the zonulin pathway can be exploited for drug delivery as well as barrier protection.[2] Jeong et al. (2025) extended this work, using FCIGRL-modified tight junction modulators to improve intestinal permeation of cyclosporin A in rats.[3]
Phase 2 Clinical Trial: The 0.5 mg Signal
The pivotal Phase 2b trial (Leffler et al., Gastroenterology, 2015) enrolled 342 adults with biopsy-confirmed celiac disease who had been on a gluten-free diet for at least 12 months but continued to experience symptoms. Patients were randomized to larazotide acetate 0.5 mg, 1 mg, or 2 mg, or placebo, taken three times daily for 12 weeks.
The primary endpoint was met at the 0.5 mg dose. Compared to placebo, larazotide 0.5 mg produced statistically significant symptom improvement (ANCOVA p=0.022, MMRM p=0.005). On exploratory endpoints, the 0.5 mg dose achieved a 26% decrease in Celiac Disease Patient Reported Outcome (CdPRO) symptomatic days (p=0.017), a 31% increase in improved symptom days (p=0.034), and more patients achieving at least 50% reduction in weekly average abdominal pain scores for 6 or more of the 12 treatment weeks (p=0.022). Non-GI symptoms including headache and tiredness also improved (p=0.010).
The dose-response relationship was unusual: the 1 mg and 2 mg doses showed no benefit over placebo. This inverted dose-response curve is not unique to larazotide. Several peptide drugs exhibit bell-shaped or U-shaped dose-response relationships where excessive receptor engagement triggers compensatory mechanisms or off-target effects that negate the therapeutic benefit. For larazotide, one hypothesis is that higher doses may over-tighten junctions to the point of interfering with normal paracellular nutrient transport, triggering adaptive loosening.
An earlier Phase 2 trial (Kelly et al., Alimentary Pharmacology & Therapeutics, 2013) tested larazotide during active gluten challenge rather than as an adjunct to a gluten-free diet. In that study, larazotide reduced gluten-induced increases in intestinal permeability (measured by lactulose/mannitol ratio) and attenuated the immune response to gluten challenge. Safety was comparable to placebo across both trials.
An even earlier Phase 2 study (Paterson et al., Alimentary Pharmacology & Therapeutics, 2007) established initial safety and tolerability in 86 celiac disease patients undergoing a gluten challenge, with larazotide 0.25 mg, 1 mg, 4 mg, or 8 mg three times daily. No serious adverse events were attributed to the drug. The intestinal permeability data in that study showed a trend toward protection but did not reach statistical significance, partly because the gluten challenge dose (2.5 g daily) may not have been sufficient to consistently induce measurable permeability changes in all patients.
The three Phase 2 trials taken together built a coherent pharmacological narrative: larazotide is safe, it reduces intestinal permeability during gluten exposure, and at the specific dose of 0.5 mg three times daily it translates that barrier effect into symptom improvement. The Phase 3 challenge was proving this modest but real effect in a larger, more diverse population.
Phase 3 Failure: The CedLara Trial
The Phase 3 CedLara trial, sponsored by 9 Meters Biopharma, enrolled 525 patients across three arms: larazotide 0.25 mg, larazotide 0.5 mg, and placebo, all taken three times daily. The trial design included a 12-week double-blind treatment phase followed by a 12-week continued safety phase.
In June 2022, 9 Meters announced that an interim analysis by an independent statistician found insufficient separation between larazotide and placebo. The number of additional patients needed to achieve statistical significance was deemed too large to justify continuing the trial. The study was discontinued.
Several factors may explain the Phase 3 failure despite positive Phase 2 results:
Endpoint selection. The Phase 3 trial used the CdPRO composite symptom score as its primary endpoint, which combines multiple GI and non-GI symptoms. Composite endpoints can dilute signals from individual symptoms that respond to treatment. The Phase 2 exploratory analyses showed the strongest effects on specific symptoms (abdominal pain, headache, tiredness) rather than on the composite score.
Patient population. The Phase 3 trial may have included patients with more heterogeneous symptom profiles than Phase 2. Celiac disease symptoms that persist on a gluten-free diet can arise from multiple causes, including unintentional gluten exposure, bacterial overgrowth, lactose intolerance, or irritable bowel syndrome overlap. Larazotide addresses only one mechanism (tight junction-mediated permeability), and patients whose symptoms stem from other causes would not benefit.
Dose selection. Phase 3 tested 0.25 mg and 0.5 mg, excluding the 1 mg and 2 mg doses that showed no efficacy in Phase 2. The decision to add a 0.25 mg arm below the effective Phase 2 dose is debatable; some analysts have suggested that the resources allocated to the 0.25 mg arm would have been better spent enlarging the 0.5 mg cohort.
Placebo response. High placebo response rates are a persistent challenge in celiac disease trials, as symptom assessment relies on patient-reported outcomes that are susceptible to expectation effects. If the placebo response was higher in Phase 3 than Phase 2, a real treatment effect could be masked.
9 Meters announced plans to conduct subgroup analyses to determine if specific patient subsets responded to treatment, and to engage with the FDA on potential next steps. As of 2026, no further trial announcements have been made.
The Phase 3 outcome also raises a broader question for peptide drug development in autoimmune diseases: can a locally acting, non-absorbed peptide generate a treatment effect large enough to detect in a patient-reported outcome trial? Larazotide's local mechanism is an advantage for safety (minimal systemic exposure) but a disadvantage for efficacy measurement, because the drug only affects one component of a complex disease. A peptide that perfectly seals tight junctions would still leave patients with symptoms from villous atrophy already present, from secondary conditions that developed during years of disease activity, or from the psychological burden of chronic dietary restriction. The lesson for future celiac drug developers is that trial design must account for the multiple sources of symptoms in a disease where the damage has already been done by the time treatment begins.
Celiac Disease: The Unmet Medical Need
The Phase 3 failure is disappointing because the unmet need is genuine. Celiac disease affects approximately 1% of the global population, though many cases remain undiagnosed. The gluten-free diet is the only management option, and it is imperfect: studies consistently show that 30-50% of patients on a strict gluten-free diet continue to experience symptoms, and many have persistent intestinal inflammation on follow-up biopsy.
The sources of ongoing symptoms are multiple. Cross-contamination of "gluten-free" foods contributes trace gluten exposure that may be sufficient to maintain low-level immune activation. Studies using highly sensitive gluten immunogenic peptide (GIP) assays in stool and urine have shown that most celiac patients on a "strict" gluten-free diet are inadvertently consuming measurable amounts of gluten, with estimates ranging from 150 to 400 mg per day in some populations (well above the 10-50 mg threshold thought to cause mucosal damage). Some patients have refractory celiac disease that does not respond to dietary restriction. Others develop secondary conditions (small intestinal bacterial overgrowth, microscopic colitis, pancreatic insufficiency) as a consequence of years of intestinal damage. The economic burden is substantial: gluten-free specialty foods cost 2-3 times more than conventional equivalents, and the social restrictions of strict dietary avoidance affect quality of life in ways that symptom scales may not fully capture.
Kamilova et al. (2022) documented altered antimicrobial peptide activity in pediatric celiac disease, showing that the innate immune landscape of the celiac gut differs from healthy controls even beyond the adaptive immune response to gliadin. This finding suggests that celiac disease involves broader disruption of gut homeostasis than the tight junction-gliadin-T cell pathway alone.[4]
Beyond Celiac: Other Tight Junction Conditions
Zonulin-mediated tight junction dysfunction is not unique to celiac disease. Elevated zonulin levels have been documented in type 1 diabetes, inflammatory bowel disease, multiple sclerosis, and several other autoimmune and inflammatory conditions. Khaleghi et al. (2021) reviewed the therapeutic potential of AT-1001 (larazotide) across these conditions, arguing that a zonulin inhibitor could have applications wherever intestinal permeability contributes to disease pathogenesis (Khaleghi et al., Current Opinion in Pharmacology, 2021).
Targeting zonulin and intestinal barrier function to prevent the onset of arthritis has been explored in preclinical models (Tajik et al., Nature Communications, 2020). In a mouse model of collagen-induced arthritis, researchers demonstrated that restoring intestinal barrier integrity with larazotide reduced systemic inflammation and joint pathology, suggesting that increased intestinal permeability is not merely a consequence of autoimmune disease but an upstream driver. The zonulin pathway may represent a shared pathogenic mechanism across autoimmune conditions, with the gut barrier serving as the gateway through which environmental triggers access the immune system.
Park et al. (2020) showed that BPC-157 rescued NSAID-induced intestinal permeability damage through mechanisms distinct from larazotide. BPC-157 stabilized intestinal permeability and enhanced cytoprotection in cell culture and animal models, but it acts through the FAK-paxillin pathway and NO system rather than the zonulin pathway. The two peptides represent complementary approaches to the same barrier dysfunction problem.[5]
Hadjiyanni et al. (2009) demonstrated that glucagon-like peptide-2 (GLP-2) reduced intestinal permeability in animal models, though it did not modify the onset of type 1 diabetes in the model studied. GLP-2's mechanism involves promoting intestinal epithelial growth and differentiation rather than directly modulating tight junction proteins, representing yet another peptide approach to barrier function.[6]
Marton et al. (2026) showed that cecropin A, an insect-derived antimicrobial peptide, affected tight junction protein expression and cytokine production in chicken intestinal cells. While not directly related to celiac disease, this finding illustrates how diverse peptides can modulate the same tight junction machinery through different upstream pathways.[7]
Gluten Peptides: The Trigger Side of the Equation
Larazotide targets the barrier side of celiac pathogenesis. The trigger side involves the gluten peptides themselves. For deeper coverage of how gliadin fragments activate the immune response, see our article on gluten-derived peptides and how they trigger celiac disease.
Brouns and Shewry (2022) examined whether gluten-derived peptides affect weight through opioid-like activity, reviewing claims that partially digested gluten produces exorphins (opioid peptides) that stimulate appetite. The evidence for this effect in humans was weak, but the review illustrates the broader pharmacological activity of gluten-derived peptides beyond their role in celiac disease.[8]
Mathiowetz (2019) reviewed design principles for intestinal permeability of cyclic peptides, documenting how peptide structure determines whether a molecule can cross the intestinal barrier. These principles apply both to therapeutic peptides designed to cross the gut wall and to understanding how gliadin peptides exploit the paracellular route when tight junctions open.[9]
What Comes Next for Celiac Drug Development
The larazotide Phase 3 failure does not invalidate the tight junction hypothesis. It demonstrates that a real but modest Phase 2 signal can be lost in a larger, more heterogeneous Phase 3 population, a pattern seen across many disease areas.
Several other peptide and non-peptide approaches to celiac disease are in development:
Gluten-degrading enzymes. Oral proteases that break down gliadin peptides in the stomach before they reach the small intestine. These include latiglutenase (ALV003) and TAK-062. The approach is complementary to larazotide: where larazotide blocks the barrier opening, glutenases destroy the trigger.
Transglutaminase inhibitors. Blocking tissue transglutaminase prevents the deamidation of gliadin peptides that makes them immunogenic. ZED1227 showed positive Phase 2 results in a gluten challenge study.
Tolerogenic peptides. Nexvax2 (a vaccine composed of three immunodominant gliadin peptides) aimed to induce immune tolerance to gluten. The Phase 2 trial did not meet its primary endpoint and development was discontinued in 2019. This represents another peptide-based approach that reached clinical trials but failed to demonstrate efficacy.
HLA-DQ2 blockers. Small molecules or peptides that prevent gliadin peptide presentation on HLA-DQ2 molecules, blocking T-cell activation at the antigen presentation step. This approach targets the most celiac-specific step in the disease cascade, since HLA-DQ2 and DQ8 are necessary (though not sufficient) for disease development.
The diversity of approaches reflects a growing understanding that celiac disease involves multiple steps, any of which could be a viable drug target. Larazotide targeted one step (barrier permeability); other approaches target gluten degradation, immune activation, or tolerance induction. Combination therapy, using a glutenase to degrade gluten in the stomach plus a tight junction modulator to reinforce the barrier, has been discussed conceptually but not yet tested clinically.
The larazotide program also left behind valuable infrastructure: the CdPRO symptom assessment tool developed for the trials, the clinical sites experienced in celiac drug trials, and the regulatory precedent of FDA engagement on celiac disease drug development. These assets benefit the entire celiac drug development field. For a comprehensive view of all peptide-based celiac approaches, see our article on peptide-based approaches to celiac disease treatment.
The Bottom Line
Larazotide acetate demonstrated a real pharmacological effect in Phase 2 trials: the 0.5 mg dose reduced celiac symptoms in patients already on a gluten-free diet, with statistically significant improvements in symptomatic days, improved days, and abdominal pain. The Phase 3 CedLara trial failed to replicate this in a larger population, leading to discontinuation in 2022. The tight junction mechanism remains valid; the drug development challenge lies in identifying which patients will respond and selecting endpoints sensitive enough to detect a modest treatment effect in a heterogeneous autoimmune disease.